

Laure Elens

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2413221/laure-elens-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

70 papers	2,484 citations	27 h-index	48 g-index
74 ext. papers	3,015 ext. citations	3.8 avg, IF	4.72 L-index

#	Paper	IF	Citations
70	Atorvastatin population pharmacokinetics in a real-life setting: Influence of genetic polymorphisms and association with clinical response. <i>Clinical and Translational Science</i> , 2021 ,	4.9	1
69	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 150-200	3.2	17
68	Effect of four ABCB1 genetic polymorphisms on the accumulation of darunavir in HEK293 recombinant cell lines. <i>Scientific Reports</i> , 2021 , 11, 9000	4.9	0
67	Genotyping in Clinical Practice: Ready for Implementation?. <i>Frontiers in Genetics</i> , 2021 , 12, 711943	4.5	5
66	Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 177-189	6.2	3
65	Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 607-616	2.8	
64	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 360-368	3.2	25
63	Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 769-782	5.5	7
62	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 261-307	3.2	163
61	A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 601-615	3.8	31
60	Detection of a rare CYP3A4 variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype. <i>Pharmacogenomics</i> , 2018 , 19, 305-310	2.6	3
59	Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines. <i>Scientific Reports</i> , 2018 , 8, 10514	4.9	6
58	Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients. <i>Scientific Reports</i> , 2018 , 8, 7359	4.9	10
57	Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. <i>Thrombosis Journal</i> , 2018 , 16, 28	5.6	25
56	Cytochrome P450 genotype and aggressive behavior on selective serotonin reuptake inhibitors. <i>Pharmacogenomics</i> , 2018 , 19, 1097-1099	2.6	
55	Pharmacogenetic associations with cytochrome P450 in antiretroviral therapy: what does the future hold?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 601-611	5.5	6
54	A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 963-975	6.2	46

53	The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. <i>Pharmacogenetics and Genomics</i> , 2017 , 27, 313-322	1.9	33
52	Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement. <i>Pharmacogenomics</i> , 2017 , 18, 1133-1142	2.6	15
51	Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22?. <i>Pharmacogenomics</i> , 2017 , 18, 1473-1480	2.6	15
50	Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. <i>Frontiers in Pharmacology</i> , 2017 , 8, 358	5.6	29
49	Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib. <i>Scientific Reports</i> , 2016 , 6, 29559	4.9	23
48	ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib. <i>Pharmacogenomics</i> , 2016 , 17, 883-90	2.6	16
47	Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC-MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a potential drug-drug interaction. <i>Clinical Biochemistry</i> , 2016 , 49, 580-6	3.5	14
46	Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism. <i>PLoS ONE</i> , 2016 , 11, e0165631	3.7	9
45	SLC22A1/OCT1 Genotype Affects O-desmethyiltramadol Exposure in Newborn Infants. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 487-92	3.2	14
44	Genetic Predisposition to Poor Opioid Response in Preterm Infants: Impact of KCNJ6 and COMT Polymorphisms on Pain Relief After Endotracheal Intubation. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 525-33	3.2	11
43	Dental Apical Papilla as Therapy for Spinal Cord Injury. <i>Journal of Dental Research</i> , 2015 , 94, 1575-81	8.1	33
42	No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia. <i>Drug Metabolism and Personalized Therapy</i> , 2015 , 30, 43-8	2	14
41	The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. <i>Pharmacogenomics Journal</i> , 2015 , 15, 144-52	3.5	33
40	Association of CYP3A variants with kidney transplant outcomes. <i>Renal Failure</i> , 2015 , 37, 562-6	2.9	8
39	The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 123-39	6.2	150
38	Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. <i>British Journal of Clinical Pharmacology</i> , 2014 , 77, 715-28	3.8	33
37	Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort. <i>Pharmacogenomics</i> , 2014 , 15, 1589-97	2.6	22
36	CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014 , 122, 60-3	2.3	20

35	Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 71-9	3.2	62
34	POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. <i>Pharmacogenomics</i> , 2014 , 15, 1963-72	2.6	14
33	Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. <i>Pharmacogenomics</i> , 2014 , 15, 1207-21	2.6	23
32	Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype. <i>Pharmacogenomics</i> , 2014 , 15, 1287-95	2.6	25
31	Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients. <i>Molecular Diagnosis and Therapy</i> , 2014 , 18, 323-31	4.5	9
30	ABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. <i>PLoS ONE</i> , 2014 , 9, e91555	3.7	33
29	CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. <i>Pharmacogenomics</i> , 2013 , 14, 137-49	2.6	40
28	Genetic variation in the PPARG gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. <i>Pharmacogenomics</i> , 2013 , 14, 1295-304	2.6	12
27	The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 1545-7	3.8	27
26	CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. <i>Pharmacogenomics</i> , 2013 , 14, 1027-36	2.6	41
25	CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. <i>Pharmacogenomics</i> , 2013 , 14, 47-62	2.6	142
24	A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. <i>Clinical Cancer Research</i> , 2013 , 19, 5210-7	12.9	22
23	Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 608-16	3.2	58
22	Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor- α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 649-57	1.9	26
21	CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. <i>Clinical Cancer Research</i> , 2013 , 19, 3316-24	12.9	72
20	Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 148-55	1.9	29
19	Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation. <i>Journal of Surgical Research</i> , 2012 , 178, 988-95	2.5	17
18	Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications. <i>Molecular Diagnosis and Therapy</i> , 2012 , 16, 331-45	4.5	15

17	The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. <i>Pharmacogenetics and Genomics</i> , 2012 , 22, 373-80	1.9	64
16	Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. <i>Clinical Cancer Research</i> , 2012 , 18, 4433-40	12.9	70
15	191 Morphine Premedication for Intubation in Preterm Infants - A Pharmacokinetic and Pharmacogenetic Report. <i>Archives of Disease in Childhood</i> , 2012 , 97, A55-A55	2.2	
14	Mycophenolic acid-related anemia and leucopenia in renal transplant recipients are related to genetic polymorphisms in CYP2C8. <i>Transplantation</i> , 2012 , 93, e39-40; author reply e41-2	1.8	11
13	Impact of CYP3A4*22 Allele on Sirolimus Dose Requirement in Kidney Transplant Patients. <i>Transplantation</i> , 2012 , 94, 575	1.8	2
12	Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors dose requirements and trough blood levels in stable renal transplant patients. <i>Pharmacogenomics</i> , 2011 , 12, 1383-96	2.6	119
11	A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. <i>Clinical Chemistry</i> , 2011 , 57, 1574-83	5.5	180
10	Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 861-6	1.9	81
9	Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 884-93	1.9	27
8	CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. <i>Pharmacogenomics</i> , 2010 , 11, 703-14	2.6	80
7	Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. <i>Pharmacogenomics</i> , 2010 , 11, 1223-34	2.6	48
6	Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. <i>Pharmacogenomics</i> , 2009 , 10, 1589-97	2.6	24
5	Acute intoxication with nevirapine in an HIV-1-infected patient: clinical and pharmacokinetic follow up. <i>Aids</i> , 2009 , 23, 1291-3	3.5	
4	Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 1885-14	3.2	28
3	Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection. <i>Clinical Chemistry</i> , 2009 , 55, 170-4	5.5	17
2	1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 873-83	1.9	83
1	CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. <i>American Journal of Transplantation</i> , 2006 , 6, 2706-13	8.7	139